Maltseva, Margarita http://orcid.org/0000-0002-8598-4357
Schubert-Bast, Susanne
Zöllner, Johann Philipp
Bast, Thomas
Mayer, Thomas
von Spiczak, Sarah
Ruf, Susanne
Trollmann, Regina
Wolff, Markus
Hornemann, Frauke
Klotz, Kerstin A.
Jacobs, Julia
Kurlemann, Gerhard
Neubauer, Bernd A.
Polster, Tilman
Syrbe, Steffen
Bertsche, Astrid
Bettendorf, Ulrich
Kluger, Gerhard
Flege, Silke
Rosenow, Felix
Kay, Lara
Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 21 June 2022
Accepted: 6 April 2023
First Online: 29 April 2023
Declarations
:
: This study received ethics approval by the Goethe-University Frankfurt (reference 40/19) and all participants provided informed consent.
: Not applicable.
: MM reports grants from GW Pharmaceuticals. SSB reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals, Zogenix, UCB Pharma, and Marinus Pharma. TB has received support from Bial, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, Neuraxpharm, Nutricia, Shire, Takeda, UCB Pharma, and Zogenix. RT reports personal fees from Desitin Pharma, Eisai, and Novartis. MW reports personal fees from Zogenix, Desitin, and Praxis Precision Medicines. KAK reports personal fees from Eisai, GW Pharmaceuticals, Zogenix, and Neuraxpharm. JJ reports personal fees from Eisai, Pendopharm, UCB Pharma, and Epilog. Her research is supported by NSERC and the Alberta Children’s Hospital Foundation. GKu reports honoraria for speaking engagements from Desitin Arzneimittel, Eisai, UCB Pharma, Takeda, Shire, Zogenix, Neuraxpharm, Stada, and GW Pharmaceuticals. SS reports personal fees from Zogenix and fees from Eisai, UCB Pharma, and Nutricia paid to his department. AB reports grants from UCB Pharma and honoraria for speaking engagements from Biogen, Desitin Arzneimittel, Eisai GmbH, GW Pharmaceuticals, Neuraxpharm, Shire/Takeda GmbH, UCB Pharma, and ViroPharma. FR reports personal fees from Angelini Pharma/Arvelle Therapeutics, Eisai, GW Pharmaceuticals/Jazz Pharma, and UCB Pharma and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF), the LOEWE Programme of the State of Hesse, and the European Union. LK reports personal fees from GW Pharmaceuticals. AS reports personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, GW/Jazz Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB Pharma, UNEEG Medical, and Zogenix. The other authors declare that they have no competing interests.